Email this article CHOICE OF TARGETED DRUG FOR SECOND-LINE METASTATIC COLON CANCER CHEMOTHERAPY
- Authors: Fedyanin M.Y.1, Tryakin A.A.1, Tjulandin S.A.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- Issue: Vol 5, No 1 (2015)
- Pages: 37-42
- Section: REVIEW
- Published: 26.05.2015
- URL: https://onco-surgery.info/jour/article/view/123
- DOI: https://doi.org/10.17650/2220-3478-2015-1-37-42
- ID: 123
Cite item
Full Text
Abstract
During the last 5 years the prognosis of metastatic colorectal cancer patients improved significantly. This results not only from increased amount of surgery for metastatic disease and use of targeted drugs in first-line treatment, but also from increased number of patients receiving effective second- and third-line chemotherapy. Currently a minimum of 7 treatment groups can be distinguished depending on prior first-line chemo- and targeted therapy. Consequentially we have less evidence-based data to guide the treatment choice for next treatment lines. This article discusses the choice of targeted drugs in combination with second-line chemotherapy.
About the authors
M. Yu. Fedyanin
N.N. Blokhin Russian Cancer Research Center
Author for correspondence.
Email: fedianinmu@mail.ru
N.N. Blokhin Russian Cancer Research Center; 24 Kashirskoye Shosse, Moscow, 115478, Russia
Russian FederationA. A. Tryakin
N.N. Blokhin Russian Cancer Research Center
Email: fake@neicon.ru
N.N. Blokhin Russian Cancer Research Center; 24 Kashirskoye Shosse, Moscow, 115478, Russia Russian Federation
S. A. Tjulandin
N.N. Blokhin Russian Cancer Research Center
Email: fake@neicon.ru
N.N. Blokhin Russian Cancer Research Center; 24 Kashirskoye Shosse, Moscow, 115478, Russia Russian Federation
References
Supplementary files
